AIM ImmunoTech Provides Summary of Ampligen® Data Supporting Synergistic Potential with Checkpoint Blockade Therapies
AIM ImmunoTech Provides Progress on Advancement of Ampligen® Clinical Development Program for the Treatment of Pancreatic Cancer
AIM ImmunoTech Announces Positive Data from Phase 2a Study Evaluating Ampligen® as a Component of a Chemokine Modulatory (CKM) Regimen for the Treatment of Colorectal Cancer Metastatic to the Liver
AIM ImmunoTech Announces Positive Data from Phase 1 Study Evaluating Ampligen® for the Treatment of Stage 4 Metastatic Triple Negative Breast Cancer
AIM ImmunoTech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
AIM ImmunoTech Announces Abstract Accepted for Presentation at 15th Annual IHPBA World Congress
AIM ImmunoTech Announces Abstract Entitled, Negative Impact of Paclitaxel on Human Breast Tumor Microenvironment and Its Reversal by the Combination of Interferon-α with TLR3 Agonist Rintatolimod, (Ampligen®), Accepted for Poster Presentation by Roswell Park Comprehensive Cancer Center at the AACR 2022 Annual Meeting
AIM ImmunoTech to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
AIM ImmunoTech Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
AIM ImmunoTech Announces Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the AACR 2022 Annual Meeting
 6   7   8   9   10     11    12   13   14   15   16 
 <<   <   >   >>